Clinical Trials Browser

Prostatic Neoplasms × cemiplimab × 90 days × Clear all

NCT06826768 2026-05-08

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Phase 1 Recruiting

Prostatic Neoplasms